Adial Pharmaceuticals, Inc. Retained Earnings
Adial Pharmaceuticals, Inc. (ADIL) had Retained Earnings of -$143.98 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$143.98M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$91.99M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$89.97M; Retained Earnings (Accumulated Deficit) as first filed -$89.97M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$87.98M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$143.98M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$91.99M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | -$89.97M 10-Q · filed 2026-08-14 | -$89.97M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$87.98M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$86.18M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$84.22M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$82.00M 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$79.92M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | -$77.73M 10-Q · filed 2024-08-13 | |
| 2023-12-31 | -$68.80M 10-K · filed 2025-03-04 | |
| 2023-09-30 | -$66.88M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$65.49M 10-Q/A · filed 2023-10-30 | |
| 2023-03-31 | -$66.58M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | -$63.67M 10-K · filed 2024-04-01 | |
| 2022-09-30 | -$60.81M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$57.70M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$53.85M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$50.94M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$45.11M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$40.79M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$36.35M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$31.52M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$28.05M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$24.71M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$22.90M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | -$20.63M 10-K · filed 2021-03-22 | |
| 2019-09-30 | -$18.57M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$16.85M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | -$14.72M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | -$12.04M 10-K · filed 2020-03-20 | |
| 2018-09-30 | -$10.77M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$2.58M 10-Q · filed 2018-09-10 | |
| 2017-12-31 | -$403.99K 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |